Approval · Notice of Compliance 27887 · 2022
DILANTIN: Notice of Compliance 27887
Issued March 31, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27887
- Date
- March 31, 2022
- Company
- Upjohn Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Make safety updates to the Adverse Reactions, Drug Interactions and Patient Medication Information sections of the Product Monograph. Convert the Product Monograph to the new 2020 format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DILANTIN | Not yet assigned | — |
Medicinal ingredients
- PHENYTOIN SODIUM 30 MG per CAP
- PHENYTOIN SODIUM 100 MG per CAP